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  The growing demand for organ donors to supply the increasing number of patients on kidney waiting lists has 
led most transplant centers to develop protocols that allow safe use of organs from donors with special clin-
ical situations previously regarded as contraindications. Deceased donors with previous hepatitis B may be a 
safe resource to increase the donor pool even if there is still controversy among transplantation centers regard-
ing the use of hepatitis B surface antigen-positive donors for renal transplantation. However, when allocated 
to serology-matched recipients, kidney transplantation from donors with hepatitis B may result in excellent 
short-term outcome. Many concerns may arise in the long-term outcome, and studies must address the evalu-
ation of the progression of liver disease and the rate of reactivation of liver disease in the recipients. Accurate 
selection and matching of both donor and recipient and correct post-transplant management are needed to 
achieve satisfactory long-term outcomes.
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Background
Kidney transplantation is now considered the best replace-
ment therapy for patients with end-stage renal disease (ESRD).
The increasing demand for available organ donors for kidney 
transplantation and the continuing shortage of organs has led 
many transplant centers to expand their acceptance criteria 
by including deceased donors with special clinical situations, 
such as older donors, non-heart-beating donors, and donors 
with potentially transmittable infections [1–3].
One strategy focuses on the use of donor kidneys with viral hep-
atitis, and several organ procurement associations have adopt-
ed the policy of accepting deceased donor kidneys with hepati-
tis B (HBV) or C (HCV) virus infection. Anti-HCV-positive donors 
can be safely used for transplantation into HCV-positive recip-
ients with no increased rate of post-transplant complications, 
but with a significant reduction of time on the waiting list for 
anti-HCV-positive ESRD patients [4–7]. In contrast, organs from 
donors with active HBV infection (HBsAg-positive) are less fre-
quently accepted due to the high risk of transmission leading to 
primary infection [8]. In addition, kidney transplant recipients of 
organs from donors with evidence of HBV Infection (hepatitis B 
surface antigen-negative/anti-hepatitis B core-positive) may be 
at higher risk of primary infection following transplantation [8].
Preexisting HBV-infected renal recipients were not at higher 
risk of kidney failure or death, but they remain at higher risk 
of liver failure compared to HBV-negative recipients [9]. Before 
introduction of safe and effective antiviral therapy, most kid-
ney transplant recipients with primary HBV infection rapid-
ly progressed to liver fibrosis and failure and, finally, death.
This review focusses on the current status of kidney trans-
plantation from HBV-positive donors, with a special focus on 
post-transplant graft and patient outcomes.
Kidney Transplantation From Hepatitis B Core 
Antibody (HBcAb)-Positive Donors
In endemic areas, the prevalence of HBcAb in the population 
of deceased organ donors is up to 24% [10,11]. The preva-
lence of HBV infection is different between countries with 
low rates (<2%) in Western Europe and the USA, intermediate 
rates (2–8%) in Mediterranean countries and Japan, and high 
rates (8–20%) in South Asia and Africa [12]. In about 10% of 
these individuals, HBV DNA is detected by polymerase chain 
reaction [13,14]. The use of renal allograft from these poten-
tial donors is crucial since excluding all of these donors may 
result in a significant decline in the global number of avail-
able renal allografts [1,15].
Although the presence of HBcAb in the blood of a potential 
organ donor may indicate an increased risk for HBV transmis-
sion to the recipient [16–18], this risk may be more accurate-
ly determined by measuring HBV-DNA than HBcAb, but HBV-
DNA measurement is not routinely recommended in standard 
deceased donors. In an interesting study by Cirocco et al. [19], 
HBV-DNA measured by PCR was negative in all hepatitis B 
surface antigen (HBsAg)-negative anti-HBc-positive donors. 
Moreover, in the 9 transplanted kidneys that were tested, the 
kidney tissue was also negative for HBV-DNA, suggesting that 
HBcAb-positive HBV-DNA negative donors are unlikely to trans-
mit infection to recipients.
Solid organ transplant recipients of HBcAb-positive organ do-
nors, exposed to immunosuppression, may have a higher risk 
of developing de novo HBV infection after transplantation.
The risk of developing a de novo HBV infection after transplan-
tation from HBcAb-positive donors may be up to 70% in liver 
transplant recipients [17,20,21], while the impact of HBcAb-
positive donors in renal transplantation appears low to negli-
gible [11,22,23]. However, some authors reported an increased 
risk of seroconversion or de novo HBV after kidney transplan-
tation from HBcAb-positive deceased donors, particularly in 
HBcAb-positive recipients [24,25].
Experimental studies demonstrated that hepadna viruses have 
a strong preference for infecting liver cells rather than extra-
hepatic organs [26], and this was confirmed in a clinical setting 
by Wachs et al. [18], who reported an HBcAb-positive multi-
organ donor who transmitted HBV to a liver allograft recipi-
ent without apparent transmission to the 2 kidney recipients.
In a series of 356 kidney transplant recipients from HBcAb-
positive donors, none of the recipients acquired HBsAg posi-
tivity, but 4/10 vaccinated patients seroconverted from HBcAb-
negative to HBcAb-positive, without any clinical or biochemical 
signs of hepatitis [11].
In their recent review, Mahboobi et al. [15] analyzed the im-
pact of HBcAb status of renal donors on viral transmission to 
recipients. The meta-analysis of 9 studies collecting a total of 
1385 eligible kidney recipients showed that the total rate of 
seroconversion after renal transplantation was 3.24%; 4 pa-
tients seroconverted to HBsAg positive (rate of seroconversion 
0.28%), 32 patients developed HBcAb after transplantation, 
and 2 became seropositive. None of these patients presented 
clinical signs of hepatitis, higher mortality, or decreased graft 
survival. In the study by Fong et al. [22], the incidence of an-
ti-HBc conversion in recipients of anti-HBc-positive and anti 
HBc-negative kidneys was 0.011 and 0.005 per year, respec-
tively. In other retrospective studies, the incidence of serocon-
version varied between 0% and 27% [11,13,16,18,22–24,27], 
1428
Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System]  
[ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica]  
[Chemical Abstracts/CAS] [Index Copernicus]
Veroux M. et al.: 
Kidney donors with hepatitis B
© Med Sci Monit, 2016; 22: 1427-1434
REVIEW ARTICLES
This work is licensed under Creative Common Attribution-
NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
but these data must be interpreted cautiously because pa-
tients who are immunosuppressed may not develop detect-
able antibody levels post-transplant [16].
In our recent experience, among 42 kidney transplant recip-
ients of a HBcAb-positive donor, none of the naïve or vacci-
nated recipients developed HBsAg seroconversion; howev-
er, 4 of 28 (14.2%) vaccinated patients seroconverted from 
HBcAb-negative to HBcAb-positive, but HBV-DNA levels were 
undetectable in the follow-up, suggesting that prophylaxis in 
these recipients is probably not warranted [2]. A document-
ed serum anti-HBs level more than 10 IU/mL after vaccination 
of a naïve patient is considered to confer protective immuni-
ty against primary HBV infection and exposure. This anti-HBs 
level confers immunity even in recipients of HBcAb-positive 
organs [28–30]. Therefore, kidneys from HBcAb-positive do-
nors are preferably allocated to successfully immunized pa-
tients or HbsAg-positive recipients [2,11,22–24].
However, the HBsAb-positive serologic status, from previous 
exposure or after vaccination, had a variable effect on serologic 
conversion, and after transplantation with an HBcAb-positive 
kidney, HBsAb-positive recipients were not completely protect-
ed [11,22,26,27]. The rate of seroconversion of kidney recipi-
ents of HBcAb-positive kidneys with protective anti-HBs con-
centration was only 4% as compared with 10% of recipients 
with no protective levels of HBsAb (<10 IU/mL) [11].
All end-stage renal disease candidates for kidney transplan-
tation should receive hepatitis B vaccine. However, a protec-
tive anti-HBs level (>10 IU/mL) after vaccination is achieved in 
only 60% of peritoneal dialysis patients, 50% of hemodialysis 
patients, and less of 20% of renal transplant recipients [31].
In HBV-naïve kidney transplant recipients who have not re-
sponded to vaccination, chronic infection after transplantation 
can be prevented by administering hepatitis B immunoglobu-
lin (HBIg) or antiviral therapy with oral nucleo(s)tide analogues 
in the post-transplant period.
Chung et al. [17] recommended a 7-day high-dose (10 000 
units intravenously daily for the first 7 days, then monthly) 
HBIg or 12-month lamivudine (100 mg every day) prophylax-
is in all recipients without evidence of HBV immunity, while 
Akalin et al. [32] suggested that 1-year prophylaxis with lami-
vudine alone without HBIg after kidney transplantation from 
an HBcAb-positive donor may protect against the risk of HBV 
transmission.
However, implementing anti-HBV prophylaxis in all recipients 
does not seem reasonable [15] since the risk of transmission 
of infection through transplantation seems to be very low [33]. 
Moreover, patients who develop inactive carrier status, as well 
as patients who become chronic carriers with active HBV rep-
lication, should be treated like immunocompetent patients 
with nucleo(s)tide analogues with high efficacy and low re-
sistance [15–30,33,34].
In the liver transplant setting, prophylaxis with lamivudine and/
or HBIg reduces rates of de novo HBV infection from 58% to 
11% in HBV non-immune recipients; 18% to 2% in previously 
vaccinated recipients; and 14% to 3% in isolated HBcAb pos-
itive recipients [28], and this benefit is higher when lamivu-
dine is used as monotherapy [28–30,35,36]. Recently, the in-
troduction of effective nucleo(s)tide analogs (NA) entecavir and 
tenofovir has improved the outcome of patients with chronic 
hepatitis B and the combination of NA and HBIg is now con-
sidered the standard of care for prophylaxis against HBV re-
currence after liver transplantation [37], while entecavir has 
replaced lamivudine as first-line therapy for treatment-naïve 
recipients in view of the propensity for drug resistance [38].
Translating these experiences in the renal transplantation set-
ting, Veroux et al. [2] applied a prophylaxis with a single dose 
of 2000 IU of HBIg in all recipients with HBsAb titer <10 IU/
mL, and this resulted in a very low incidence of seroconver-
sion when compared with patients who did not receive prophy-
laxis. All HBcAb-positive patients who underwent prophylaxis 
did not have HBV reactivation, while 2 patients who did not 
undergo prophylaxis developed a subclinical reactivation [2].
More recently, Ouseph et al. [14] proposed a different approach 
– recipients of HBc-positive kidneys start prophylaxis with la-
mivudine or HBIg; if the recipients have been vaccinated and 
the titer is protective, HBV-DNA is monitored every 3 months, 
and prophylaxis is suspended when HBV-DNA is undetectable.
If the recipients are not vaccinated and the HBV-DNA is neg-
ative, the HBV-DNA is followed monthly, and the recipient is 
revaccinated with 3 doses.
While most studies reported similar graft and patient surviv-
al in kidney transplantation from HBcAb-positive donors com-
pared to those from HBcAb-negative donors [2,11,14,23,24], 
Fong et al. [22] reported lower 1- and 3-year graft and patient 
survival in kidney recipients of HBcAb-positive donors com-
pared to those from HBcAb-negative donors. However, the re-
duction in survival was attributable to donor and recipient fac-
tors independent of HBcAb status.
Most of the clinical studies reported an increase in trans-
aminase levels in 0–26% of patients [11,16,18,22–24], but 
Alkalin et al. [32] suggested that recipients at higher risk for 
elevated transaminase levels were those who were co-infect-
ed with hepatitis C.
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In summary, existing data support the use of HBcAb-positive 
organ donors for kidney transplantation. HBcAb-positive kid-
neys should be used in successfully vaccinated or in HBsAg-
positive patients.
Current evidence does not suggest using extensively prophy-
laxis for recipients of HBcAb-positive kidneys: however, strict 
surveillance serologies are mandatory and an HBIg single-shot 
prophylaxis may reduce the risk of HBV seroconversion or re-
activation in all naïve or HBcAb-positive transplant recipients.
Kidney Transplantations From HBsAg-Positive 
Donors
In geographic areas endemic for HBV infection, HBsAg carrier 
rates are so high (10–20%) [29] that exclusion of HBsAg do-
nors from the donor pool would significantly reduce the sup-
ply of kidney allografts.
It is generally accepted that transplanting an HBsAg-positive 
allograft into an HBsAg-negative recipient carries a significant 
risk of novo infection. Although the presence of preexisting ac-
quired immunity after vaccination or after previous HBV infec-
tion should protect the recipient from primary de novo HBV in-
fection, most transplant centers do not transplant kidneys from 
HBsAg-positive donors, and in most countries these donors can 
be transplanted only in matched HBsAg-positive recipients.
Before introduction of anti-viral treatment, HBsAg-positive 
kidney transplant recipients had a significantly lower survival 
compared to HBsAg-negative recipients, and much of the mor-
tality occurred relatively early, mainly due to progressive liver 
disease [37,38], and HBsAg-positivity was associated with a 
2.49-fold higher risk of death after kidney transplantation [39].
Treatment of HBsAg-positive renal transplant recipients with 
NA confers long-term survival benefit, and rescue therapy with 
adefovir or entecavir is effective and well tolerated in patients 
who developed resistance to lamivudine [40].
Antiviral therapy with lamivudine is effective in suppressing 
HBV DNA and improving transaminase levels [41], and is as-
sociated with improved graft survival nearly comparable to 
HBsAg-negative recipients [42].
Despite reduced mortality as a result of decreased hepat-
ic complications observed in patients treated with lamivu-
dine, liver-related deaths accounts for 40% of all mortalities 
in HBsAg-positive patients [42]. Prolonged antiviral treatment 
with lamivudine is associated with progressive increase in drug 
resistance, with a cumulative probability of developing lami-
vudine-resistance of 60% at 69 months [42].
The nephrotoxic drug adefovir has been used mainly in patients 
with lamivudine-resistance. Adefovir as add-on treatment with 
lamivudine led to 88% undetectable HBV-DNA at 36 months 
in lamivudine-resistant kidney transplant recipients, and nor-
malization of ALT was achieved in 92.8% of patients after 12 
months of treatment [43]. However, evidence of nephrotox-
icity was reported in up to 50% of kidney transplant recipi-
ents, requiring in most cases treatment discontinuation [42].
Entecavir has been recently introduced as part of antiviral ther-
apy of HBsAg-positive kidney transplant recipients, due to its 
high resistance barrier and favorable safety profile [42,44]. 
Entecavir is associated with a more potent response than la-
mivudine and the tolerability profile is favorable but, when 
used in lamivudine-resistant kidney allograft recipients, the 
virological response could be variable and relatively slower 
compared with treatment-naïve patients [42,44].
There are limited data on the use of tenofovir in kidney trans-
plant recipients, and there are concerns about its potential 
nephrotoxicity [45,46].
Although antiviral treatment should be continued lifelong af-
ter kidney transplantation due to the risk of viral reactivation 
and progression of liver disease, a recent study reported a suc-
cessful withdrawal of antiviral treatment in 4 HbsAg-positive 
renal transplant recipients with complete suppression of HBV 
infection having received antivirals for 14.3 months. They re-
mained HBV-DNA negative for a median of 60.5 months [47].
Most studies investigating use of HBsAg-positive kidney do-
nors have shown that the policy of transplanting such kidneys 
to HBsAg-positive recipients with natural immunity is reason-
able and seems to be safe [48–52].
An interesting study comparing patient survival among 24 
HBsAg-positive recipients of kidneys from HBsAg-positive do-
nors with that among 42 HBsAg-positive recipients of kid-
neys from HBsAg-negative donors [53] reported no statisti-
cally significant differences between the 2 groups in number 
of episodes of hepatitis. However, recipients of kidneys from 
HBsAg-negative deceased donors had significantly higher 
1- and 5-year survival rates than recipients of kidneys from 
HBsAg-positive donors.
In a recent study, we reported 5 successful kidney transplan-
tations from HBsAg-positive donors into HBsAg-positive recip-
ients, with no post-transplant elevation of transaminases and 
a significant reduction of waiting time for transplantation [49].
Recent observations suggest the opportunity to transplant 
HBsAg-positive kidneys into HBsAb-positive recipients, and re-
cipients were given hepatitis B immunoglobulin at the time of 
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and after transplantation. Lamivudine was also recommended 
for these recipients [15,37,38,50].
Asuman et al. [52] compared clinical and biochemical param-
eters of kidney transplant recipients of HBsAg-positive living 
donors (group 1, 111 patients) with a group of recipients of 
HBsAg-negative donors (group 2, 2057 patients). Living kid-
ney transplantation from HBsAg-positive/HBV DNA-negative 
donor was performed only if recipients displayed an HBsAb ti-
ter >10 mIU/mL. Since all recipients were naturally or vaccine-
induced HBsAb-positive at the time of transplantation, they 
received neither HBIg nor lamivudine. This study demonstrat-
ed that 1-, 2-, and 4-year serum creatinine levels, glomerular 
filtration rates, and liver function test results were similar be-
tween the 2 groups without de novo hepatitis B virus infection 
throughout the study period. Moreover, graft and patient sur-
vivals were similar between the 2 groups. Another study [53] 
reported no de novo HBV infection in 35 HBV-immune (anti-
HBs >10 IU/mL) patients who underwent kidney transplanta-
tion from HBsAg-positive, HBV DNA-negative living donors.
Although these studies may be criticized because an HBsAb ti-
ter >10 IU/L may be not completely protective against the risk 
of viral transmission, HBsAg-positive living donors may be an 
attractive source for expanding the donor pool in those coun-
tries where HBV is endemic and the rate of deceased donor 
organ donation is low or insufficient.
In their large series, Jiang et al. [54] compared the clinical out-
comes in 373 HBsAb-positive kidney transplant recipients re-
ceiving a kidney from either HBsAg-positive donors (n=65) or 
HBsAg-negative donors. Recipients of HBsAg-positive grafts re-
ceived a prophylaxis with 400 IU of HBIg on the day of surgery 
and again 1 month after transplantation, if the donor had un-
detectable serum HBV DNA; if the donor had detectable HBV 
DNA, the recipient received weekly HBIg for 12 weeks and dai-
ly lamivudine 100 mg for 6 months.
There were no differences in graft or patient survival between 
the 2 groups, and none of the 7 recipients receiving a graft 
from an HBV DNA-positive donor displayed evidence of HBV 
infection 20 months after transplantation.
In a recent study, Yilmaz et al. [55] compared the long-term 
outcomes in 26 kidney transplant recipients receiving a kidney 
from HBsAg-positive, HBV-DNA positive and HBcAb positive do-
nors with 52 kidney transplant recipients of HBsAg-negative, 
HBcAb-negative donors. All recipients were HBsAg-negative 
and HbsAb levels were similar and protective in both groups 
(452±384 vs. 448±431, p=0.724), and recipients of HBsAg-
positive donors were treated with lamivudine. The rate of 
acute hepatitis was significantly higher in recipients of HBsAg-
positive donors (11% vs. 0%, p=0.012), and all of the patients 
who developed an acute hepatitis had a HBsAb protective ti-
ter after vaccination, while none of the patients who had ac-
quired natural immunity against HBsAg developed acute hep-
atitis, suggesting that vaccination may not completely protect 
these patients against the risk of viral transmission.
Despite a higher incidence of acute hepatitis, kidney trans-
plant recipients of HBsAg-positive, HBV-DNA positive donors 
had similar graft and patient survival rates, acute rejection 
rates, and post-transplant complications compared to recipi-
ents of HBsAg-negative kidneys.
Taken together, these studies confirmed that protective im-
munity to HBV (acquired through previous infection or vacci-
nation) prevents chronic HBV infection in recipients of HBsAg-
positive kidneys.
Transplantation of HBsAg-positive kidneys into HBV-naïve re-
cipients may result in primary infection of the recipient, who 
may achieve long-term HBV suppression with NA antiviral drugs 
(entecavir and tenofovir), which prevents progression to cir-
rhosis and liver failure [8,37,38]. However, these patients re-
main at higher risk for hepatocellular carcinoma [8].
Although some authors reported the possibility of fulminant 
hepatic failure after kidney transplantation from an HBsAg-
positive donor into an HBsAg-negative immunized recipients 
[56], in a recent study, Chancharoenthana et al. [30] compared 
outcomes of kidney transplantation between HBsAg-negative 
recipients with anti-HBs titer above 100 mIU/mL undergoing 
transplantation from HBsAg-positive donors without HBV vire-
mia (n=43) and HBsAg-negative donors (n=86). After a mean 
follow-up of 58.2 months, there were no significant differences 
in graft and patients survivals, and no HBV-infective markers 
(HBsAg, HBcAb, HBeAg, HBV DNA) were detected in the HBsAg-
positive donor group. Moreover, recipients of HBsAg-positive 
donors with no prophylaxis (n=20) had similar outcomes with 
those treated with lamivudine alone (n=21) or lamivudine in 
combination with HBIg (n=2). This study, therefore, suggested 
that kidney transplantation from HbsAg-positive donors into 
HbsAg-negative recipients with non-protective anti-HBs titer 
provide excellent graft and patient survival without evidence 
of HBV transmission [30].
Despite these surprising results, this practice is not advocat-
ed in most transplant centers, and transplantation of a kid-
ney from an HbsAg-positive donor into a HBV-naïve recipient 
should be considered only in urgent situations where the ben-
efit of kidney transplantation outweigh the risk of acquired 
HBV infection.
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Conclusions
HBV-infected organ donors may be a relevant organ source 
for kidney transplantation. Kidneys from HBcAb-positive organ 
donors may be transplanted safely in successfully vaccinated 
or in HBsAg-positive patients with an anti-HBs titer >10 IU/L; 
these organ could be allocated even to HBsAb-negative recip-
ients with a very low risk of transmission. In these patients, 
an antiviral prophylaxis with lamivudine or, alternatively, with 
entecavir, may be warranted.
Kidney transplantation from HBsAg-positive donor kidneys may 
be safely allocated in HBsAg-positive recipients. All transplant 
recipients should undergo prophylaxis with lamivudine or, in 
case of failure, with adefovir or entecavir, which can confer 
long-term survival benefits.
Kidney transplantation in HBsAb-positive recipients with an an-
ti-HBs titer of at least >10 IU/L could be performed safely with 
post-transplant HBV monitoring and, eventually, with the use of 
antivirals to prevent the risk of hepatitis B progression. Kidney 
transplantation from HBsAg-positive donors to HBV-naïve re-
cipients, although some promising results have been report-
ed, needs further data to be extensively adopted, and should 
be limited to urgent life-threatening conditions (Figure 1).
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Figure 1.  Kidney transplantation from anti-HBc positive donors can be performed safely without the need for prophylaxis in recipients 
with HBV immunity (>10 IU/mL). In patients with low titer of anti-HBs (<10 IU/mL), a pre-transplant vaccine booster should 
be administered and, if successful, no prophylaxis is needed. In patients not responding to vaccine, consider prophylaxis with 
hepatitis B Immunoglobulin or lamivudine. HBsAg-positive recipients receiving a kidney graft from an HBcAb-positive donor 
should receive prophylaxis with entecavir or tenofovir. Kidney transplantation from HbsAg-positive donors should be limited 
to HbsAg-positive recipients (consider for prophylaxis with entecavir) or successfully immunized recipients (anti-HBs titer >10 
IU/mL, no need for prophylaxis). In anti-HBc-negative/anti-HBs-negative (<10 IU/mL) recipients, administer vaccine boosters 
pretransplant. If unsuccessful, lamivudine should be administered from time of transplant. If anti-HBs titer increases >10 
IU/mL, no post-transplant prophylaxis is required. Transplant into naïve recipients should be avoided or limited to those 
recipients in whom the potential benefit of receiving an HBsAg-positive kidney outweigh the risk of post-transplant de novo 
hepatitis [from ref. 1, 2, 8, 11, 14, 15, 22, 23, 29, 30, 37, 38, 46]. HBV – hepatitis B virus; HBsAg – hepatitis B surface antigen; 
HBcAb – hepatitis B core antibody; HBsAb – hepatitis B antibody.
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HBsAg positive
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positive recipient
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